Velpanat Tablet is a combination medicine used for the treatment of chronic hepatitis C infection. It may also be used in combination with ribavirin for patients with advanced cirrhosis. This medicine is not recommended for use in patients with a known history of hepatitis B infection due to the increased risk of serious adverse reactions. This medicine is not recommended for use in patients with a known allergy to velpatasvir, sofosbuvir, or any other inactive ingredients present in the formulation.

First Launch of Generic Epclusa

Generic Epclusa (Sofosbuvir/Velpatasvir) is a medication for the treatment of hepatitis C all genotypes between 1 to 6.
The first generic Epclusa was released by Bangladesh pharmaceutical company Beacon Pharmaceutical with the brand name of Sofosvel.

However, the Bangladesh Company was not used Gilead technology to manufacture generic Epclusa. They get API from other countries and make their own first independent Generic Epclusa. Most of the peoples generally prefer Indian generic Epclusa.

International Sofosbuvir+Velpatasvir brand cost is approx $74,760 per treatment. Most of the peoples worldwide, not able to afford this price. Even insurances companies also not easily approve this treatment. Generic is the only hope for those peoples. The generic medication Velpanat price about 97% lower than the original drugs in India. Velpanat has become so popular that people across various countries preferred to be treated via Velpanat. Most of the patients worldwide seek to acquire the Indian Hepatitis C treatment Velpanat and other Indian generic Epclusa. Normally, the price of Velpanat and other generic Epclusa Cost Sofosbuvir 400 mg and Velpatasvir 100 mg in India price less than 800 US dollars per treatment